Invention Grant
- Patent Title: Antibodies to mucin-16 (MUC16), encoding polynucleotides and methods of treating MUC16-positive cancer
-
Application No.: US17292749Application Date: 2019-11-14
-
Publication No.: US12168696B2Publication Date: 2024-12-17
- Inventor: David Spriggs , Javier Morales , Yoko Nakano , Hong Liu
- Applicant: Memorial Sloan Kettering Cancer Center , Eureka Therapeutics, Inc.
- Applicant Address: US NY New York; US CA Emeryville
- Assignee: Memorial Sloan Kettering Cancer Center,Eureka Therapeutics, Inc.
- Current Assignee: Memorial Sloan Kettering Cancer Center,Eureka Therapeutics, Inc.
- Current Assignee Address: US NY New York; US CA Emeryville
- Agency: Foley & Lardner LLP
- International Application: PCT/US2019/061503 WO 20191114
- International Announcement: WO2020/102555 WO 20200522
- Main IPC: C07K16/30
- IPC: C07K16/30 ; A61K39/00 ; A61P35/00
Abstract:
Provided herein are compositions, methods, and uses involving anti-Mucin-16 (MUC16) agents that immunospecifically bind an epitope of Mucin-16 (MUC16). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer and diseases associated with positive MUC16 expression.
Public/Granted literature
- US20210403597A1 ANTIBODIES TO MUCIN-16 AND METHODS OF USE THEREOF Public/Granted day:2021-12-30
Information query
